<DOC>
	<DOCNO>NCT01677104</DOCNO>
	<brief_summary>Incretins become successful drug target repertoire medication use treatment type 2 diabetes . However little known potential benefit GLP-1 vascular system human , independent glucose lower action data derive ex vivo study animal . Particularly little know clinically relevant benefit GLP-1 analogue microvascular system individual type 2 diabetes . The vascular effect could medicate endogenous GLP-1 ( 9,36 ) amide , breakdown product GLP-1 ( 7,36 ) amide low affinity GLP-1 receptor . The investigator hypothesis co-administration DPP-IV inhibitor lack beneficial effect GLP-1 vascular system GLP-1 ( 9,36 ) amide produce body . The study aim examine response GLP-1 analogue small blood vessel examine effect addition DPP-IV inhibition healthy lean individual , obese individual subject Type 2 diabetes .</brief_summary>
	<brief_title>The Microvascular Function GLP-1 Its Analogues</brief_title>
	<detailed_description />
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Lean BMI ≤ 25.0 kg/m2 Obese BMI ≥30.0kg/m2 Non diabetic subject subject Type 2 diabetes stable medication least 3 month cardiovascular disease Raynaud 's disease current treatment antihypertensive lipid lower therapy severe hepatic impairment pregnancy lactation subject Type 2 diabetes insulin therapy subject Type 2 diabetes sulphonylureas subject Type 2 diabetes incretin base therapy subject Type 2 diabetes peripheral vascular disease subject Type 2 diabetes history advance retinopathy subject Type 2 diabetes advance nephropathy subject Type 2 diabetes uncontrolled diabetes ( HbA1c &gt; 8.5 % )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>DPP-IV inhibitor</keyword>
	<keyword>microcirculation</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Linagliptin</keyword>
</DOC>